At the 34th Annual Congress of the European Academy of Dermatology and Venereology (EADV), which took place September 17-20 in Paris, research was presented titled “Dupilumab Safety and Efficacy Up to 3 Years Across Racial Subgroups in…
Efficacy and Safety of Dupilumab in AD Across Diverse Pediatric Populations: A Q&A With Elaine Siegfried, MD
